Investment Rating - The report assigns a "Buy-A" investment rating with a 6-month target price of 79 yuan, which corresponds to a dynamic price-to-earnings ratio of 35 times for 2025 [4][6]. Core Insights - The company demonstrated stable performance in Q3 2025, achieving revenue of 1.243 billion yuan (up 3.28% year-on-year) and a net profit of 434 million yuan (down 9.72% year-on-year) [1]. - The overseas business significantly contributed to overall growth, with a 21.07% year-on-year increase in overseas main business revenue, and a 37.23% increase in overseas reagent business driven by instrument installations [2]. - The sales of the high-speed immunoassay analyzer X8 continued to rise, and the X10 model was launched in Q3 2025, with cumulative sales of X8 reaching 4,545 units by the end of Q3 2025. The self-developed T8 assembly line, launched in June 2024, achieved cumulative sales of 245 units, with 158 units installed in the first three quarters of 2025 [3]. Financial Performance Summary - The company expects revenue growth rates of 3.4%, 15.2%, and 13.8% for 2025, 2026, and 2027 respectively, while net profit growth rates are projected at -2.4%, 16%, and 17.7% for the same periods [4][5]. - For 2025, the company anticipates a revenue of 4.69 billion yuan and a net profit of 1.784 billion yuan, with an earnings per share (EPS) of 2.27 yuan [5][9]. - The financial metrics indicate a net profit margin of 38.0% for 2025, with a return on equity (ROE) of 18.9% [5][9].